Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- University of Washington
- Study ID
- NCT07598734
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Postoperative Knee Function
- Quality of Life After Primary TKA
- Sleep Quality Post-TKA
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Doxepin 6 mg — DRUGDoxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
- Ramelteon 8 mg — DRUGRamelteon 8 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
- Placebo Tablets — DRUGPlacebo administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Study Details
Many patients experience poor sleep during recovery after total knee arthroplasty (TKA). Disturbed sleep can last weeks to months and may worsen pain, slow healing, and reduce overall quality of life. Few safe, effective, evidence-based options exist to improve sleep during this recovery period. This study aims to determine whether the medications doxepin, either alone or in combination with ramelteon, can improve sleep quality during early recovery after TKA. The investigators will also evaluate whether improved sleep leads to better pain control, knee function, and overall quality of life.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- May 2026
- Primary completion
- Jun 30, 2028
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 129 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Doxepin 6 mgParticipants receive doxepin 6 mg and matching placebo orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
- Experimental: Doxepin 6 mg and Ramelteon 8mgParticipants receive doxepin 6 mg and ramelteon 8 mg orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
- Placebo Comparator: PlaceboParticipants receive 2 matching placebos orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
Primary Outcome Measure
Insomnia Severity Index (ISI) scores (sleep quality) [ Time Frame: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively ]
Central Contacts
- Gerald Y Liao, MS617-710-7211
- Nicholas M Hernandez, MD530-514-1275
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Washington Medical Center Hip & Knee Center | Seattle | Washington | 98133 | Nicholas M Hernandez, MD (PRINCIPAL_INVESTIGATOR) |